ArticleFrontiers in oncology2024

Sorafenib maintenance in FLT3-ITD mutated AML after allogeneic HCT: a real-world, single-center experience.

Elisa Diral et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.